Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) play a crucial role in cancer treatment, particularly in breast cancer, and their mechanism of drug resistance is a topic of global interest in research. Hence, it is vital to comprehend the distinctions between various CDK4/6i, including their mechan...
Furkejuvvon:
| Váldodahkkit: | , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Frontiers Media S.A.
2023-07-01
|
| Ráidu: | Frontiers in Pharmacology |
| Fáttát: | |
| Liŋkkat: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1212986/full |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|